JPMorgan Chase & Co. set a GBX 7,900 ($103.23) target price on AstraZeneca (LON:AZN) in a research report report published on Wednesday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other research firms have also commented on AZN. UBS Group reaffirmed a sell rating and set a GBX 5,700 ($74.48) target price (up previously from GBX 5,400 ($70.56)) on shares of AstraZeneca in a report on Wednesday, August 14th. Deutsche Bank reaffirmed a buy rating and set a GBX 6,900 ($90.16) target price on shares of AstraZeneca in a report on Friday, July 26th. Shore Capital reaffirmed a buy rating on shares of AstraZeneca in a report on Tuesday. Kepler Capital Markets set a GBX 6,470 ($84.54) target price on shares of AstraZeneca and gave the stock a buy rating in a report on Monday, May 13th. Finally, Barclays lifted their target price on shares of AstraZeneca from GBX 7,600 ($99.31) to GBX 7,800 ($101.92) and gave the stock an overweight rating in a report on Friday, August 16th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of GBX 6,688.24 ($87.39).
AZN opened at GBX 7,313 ($95.56) on Wednesday. The company has a fifty day moving average price of GBX 6,885.06 and a two-hundred day moving average price of GBX 6,283.40. The company has a debt-to-equity ratio of 144.48, a quick ratio of 0.74 and a current ratio of 0.95. AstraZeneca has a 52 week low of GBX 5,312 ($69.41) and a 52 week high of GBX 7,475.15 ($97.68). The firm has a market capitalization of $95.94 billion and a PE ratio of 42.72.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: Call Option Volume
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.